FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026897105> ?p ?o ?g. }

• W3026897105 endingPage "188" @default.
• W3026897105 startingPage "178" @default.
• W3026897105 abstract "Purpose CD19-targeting chimeric antigen receptor T-cell (CART) therapy has emerged as a promising treatment for relapsed/refractory aggressive B-cell lymphoma (r/rABL), culminating in 2 US Food and Drug Administration–approved therapies: tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel). Following leukapheresis and in preparation for CART infusion, contemporary bridging and lymphodepletion regimens rely mostly on cytotoxic chemotherapy. Here, in a cohort of patients treated with commercial tisa-cel and axi-cel, we show that bridging-RT may offer a supplemental approach. Methods and Materials Thirty-one patients receiving commercial tisa-cel (n = 13) or axi-cel (n = 18) between August 2018 and February 2019 for r/rABL were retrospectively reviewed. Patients were categorized into 2 groups: (1) bridging-RT within 30 days of CART infusion or (2) nonbridging-RT (NBRT), in which patients received either remote RT greater than 30 days before CART infusion or no prior RT. Results Five patients received bridging-RT within 30 days of CART infusion. Median bridging-RT dose was 37.5 Gy and was completed a median of 13 days before infusion. No grade 3 (G3) or higher RT-toxicities occurred. No patients in the bridging-RT group experienced G3 or higher CART-related toxicities (CRS or neurotoxicity), and 23% (n = 6) and 15% (n = 4) experienced G3-5 CRS and G3-5 neurotoxicity in the NBRT group, respectively. Overall treatment response in the bridging-RT and NBRT groups was 80% and 64%, respectively. The axi-cel CART product was associated with CRS (odds ratio [OR] = 26.67, P = .001) and CRS correlated with neurotoxicity (OR = 12.22, P = .028). There was a trend toward an association for CRS with metabolic tumor volume (OR = 1.06/mL, P = .141) and TLG (OR = 1.01/mL x standard uptake value, P = .099). Conclusions Bridging-RT before commercial CART does not appear to increase the risk for CART-related toxicities or negatively affect outcomes in r/rABL patients. No G3 or higher RT-toxicities occurred in this series. Pretreatment metabolic tumor burden may be associated with CART-associated CRS; however, larger patient numbers are required to elucidate significant associations. Future work to prospectively assess the value of bridging-RT is warranted. CD19-targeting chimeric antigen receptor T-cell (CART) therapy has emerged as a promising treatment for relapsed/refractory aggressive B-cell lymphoma (r/rABL), culminating in 2 US Food and Drug Administration–approved therapies: tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel). Following leukapheresis and in preparation for CART infusion, contemporary bridging and lymphodepletion regimens rely mostly on cytotoxic chemotherapy. Here, in a cohort of patients treated with commercial tisa-cel and axi-cel, we show that bridging-RT may offer a supplemental approach. Thirty-one patients receiving commercial tisa-cel (n = 13) or axi-cel (n = 18) between August 2018 and February 2019 for r/rABL were retrospectively reviewed. Patients were categorized into 2 groups: (1) bridging-RT within 30 days of CART infusion or (2) nonbridging-RT (NBRT), in which patients received either remote RT greater than 30 days before CART infusion or no prior RT. Five patients received bridging-RT within 30 days of CART infusion. Median bridging-RT dose was 37.5 Gy and was completed a median of 13 days before infusion. No grade 3 (G3) or higher RT-toxicities occurred. No patients in the bridging-RT group experienced G3 or higher CART-related toxicities (CRS or neurotoxicity), and 23% (n = 6) and 15% (n = 4) experienced G3-5 CRS and G3-5 neurotoxicity in the NBRT group, respectively. Overall treatment response in the bridging-RT and NBRT groups was 80% and 64%, respectively. The axi-cel CART product was associated with CRS (odds ratio [OR] = 26.67, P = .001) and CRS correlated with neurotoxicity (OR = 12.22, P = .028). There was a trend toward an association for CRS with metabolic tumor volume (OR = 1.06/mL, P = .141) and TLG (OR = 1.01/mL x standard uptake value, P = .099). Bridging-RT before commercial CART does not appear to increase the risk for CART-related toxicities or negatively affect outcomes in r/rABL patients. No G3 or higher RT-toxicities occurred in this series. Pretreatment metabolic tumor burden may be associated with CART-associated CRS; however, larger patient numbers are required to elucidate significant associations. Future work to prospectively assess the value of bridging-RT is warranted." @default.
• W3026897105 created "2020-05-29" @default.
• W3026897105 creator A5005058090 @default.
• W3026897105 creator A5005236105 @default.
• W3026897105 creator A5010621831 @default.
• W3026897105 creator A5013007800 @default.
• W3026897105 creator A5014785600 @default.
• W3026897105 creator A5015896987 @default.
• W3026897105 creator A5018891792 @default.
• W3026897105 creator A5019666650 @default.
• W3026897105 creator A5030212782 @default.
• W3026897105 creator A5039052702 @default.
• W3026897105 creator A5039108982 @default.
• W3026897105 creator A5039776999 @default.
• W3026897105 creator A5042844727 @default.
• W3026897105 creator A5046927381 @default.
• W3026897105 creator A5055562401 @default.
• W3026897105 creator A5065983314 @default.
• W3026897105 creator A5079985074 @default.
• W3026897105 creator A5080630441 @default.
• W3026897105 creator A5088286702 @default.
• W3026897105 creator A5090230371 @default.
• W3026897105 date "2020-09-01" @default.
• W3026897105 modified "2023-10-16" @default.
• W3026897105 title "Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma" @default.
• W3026897105 cites W1986579589 @default.
• W3026897105 cites W2034892179 @default.
• W3026897105 cites W2099570622 @default.
• W3026897105 cites W2118796952 @default.
• W3026897105 cites W2119147717 @default.
• W3026897105 cites W2130997237 @default.
• W3026897105 cites W2133345449 @default.
• W3026897105 cites W2150587745 @default.
• W3026897105 cites W2305142474 @default.
• W3026897105 cites W2744261860 @default.
• W3026897105 cites W2756071038 @default.
• W3026897105 cites W2773804840 @default.
• W3026897105 cites W2775369717 @default.
• W3026897105 cites W2782920912 @default.
• W3026897105 cites W2790865199 @default.
• W3026897105 cites W2793787928 @default.
• W3026897105 cites W2800595080 @default.
• W3026897105 cites W2897903823 @default.
• W3026897105 cites W2903062212 @default.
• W3026897105 cites W2904820558 @default.
• W3026897105 cites W2905654445 @default.
• W3026897105 cites W2907190120 @default.
• W3026897105 cites W2913039309 @default.
• W3026897105 cites W2942621614 @default.
• W3026897105 cites W2943335541 @default.
• W3026897105 cites W2950480110 @default.
• W3026897105 cites W2952960709 @default.
• W3026897105 cites W2954869918 @default.
• W3026897105 cites W2972833226 @default.
• W3026897105 cites W2972848890 @default.
• W3026897105 cites W2984129777 @default.
• W3026897105 doi "https://doi.org/10.1016/j.ijrobp.2020.05.014" @default.
• W3026897105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32446950" @default.
• W3026897105 hasPublicationYear "2020" @default.
• W3026897105 type Work @default.
• W3026897105 sameAs 3026897105 @default.
• W3026897105 citedByCount "51" @default.
• W3026897105 countsByYear W30268971052020 @default.
• W3026897105 countsByYear W30268971052021 @default.
• W3026897105 countsByYear W30268971052022 @default.
• W3026897105 countsByYear W30268971052023 @default.
• W3026897105 crossrefType "journal-article" @default.
• W3026897105 hasAuthorship W3026897105A5005058090 @default.
• W3026897105 hasAuthorship W3026897105A5005236105 @default.
• W3026897105 hasAuthorship W3026897105A5010621831 @default.
• W3026897105 hasAuthorship W3026897105A5013007800 @default.
• W3026897105 hasAuthorship W3026897105A5014785600 @default.
• W3026897105 hasAuthorship W3026897105A5015896987 @default.
• W3026897105 hasAuthorship W3026897105A5018891792 @default.
• W3026897105 hasAuthorship W3026897105A5019666650 @default.
• W3026897105 hasAuthorship W3026897105A5030212782 @default.
• W3026897105 hasAuthorship W3026897105A5039052702 @default.
• W3026897105 hasAuthorship W3026897105A5039108982 @default.
• W3026897105 hasAuthorship W3026897105A5039776999 @default.
• W3026897105 hasAuthorship W3026897105A5042844727 @default.
• W3026897105 hasAuthorship W3026897105A5046927381 @default.
• W3026897105 hasAuthorship W3026897105A5055562401 @default.
• W3026897105 hasAuthorship W3026897105A5065983314 @default.
• W3026897105 hasAuthorship W3026897105A5079985074 @default.
• W3026897105 hasAuthorship W3026897105A5080630441 @default.
• W3026897105 hasAuthorship W3026897105A5088286702 @default.
• W3026897105 hasAuthorship W3026897105A5090230371 @default.
• W3026897105 hasConcept C10205521 @default.
• W3026897105 hasConcept C121332964 @default.
• W3026897105 hasConcept C121608353 @default.
• W3026897105 hasConcept C126322002 @default.
• W3026897105 hasConcept C127413603 @default.
• W3026897105 hasConcept C141071460 @default.
• W3026897105 hasConcept C142424586 @default.
• W3026897105 hasConcept C143998085 @default.
• W3026897105 hasConcept C2777275308 @default.
• W3026897105 hasConcept C2777371436 @default.
• W3026897105 hasConcept C2777701055 @default.

• next